India acts against 90% of high-risk drug facilities inspected since late 2022
India’s drug regulator says roughly 860 of more than 960 risk-based inspections and audits led to action, including production stoppages and licence suspensions. The enforcement drive raises compliance pressure on manufacturers and could affect pharmacy supply reliability.
India’s drug regulator has acted against roughly 860 high-risk pharmaceutical facilities after more than 960 inspections, including production stoppages and licence suspensions. The quality drive affects manufacturers and India’s pharmacy supply chain, with CDSCO expanding digital monitoring and AI-assisted inspections.
Why this matters
No related recent CDSCO signals are listed. The inspection results indicate intensified enforcement, raising compliance pressure on drug manufacturers and potential pharmacy supply risks.
Retail-company signals are accelerating, up 314875% QoQ.